NEW YORK (GenomeWeb News) – Vermillion today announced an agreement with Quest Diagnostics for the launch of the OVA1 ovarian cancer test in India.
The two firms are targeting the launch for the second quarter. In a statement, Gail Page, president and CEO of Austin, Texas-based Vermillion said that with 350 million women, India is an "outstanding market opportunity. … Vermillion is now poised for growth both domestically and internationally as we continue to develop our international strategy in concert with the efforts already underway in the US."
Quest already was marketing OVA1, which received clearance from the US Food and Drug Administration in September 2009, in the US. The test was the first protein-based in vitro diagnostic multivariate index assay to receive such approval.
Financial and other terms of today's deal were not disclosed.
Quest operates a 65,000 square-foot facility in Gurgaon, in the National Capital Region of India, that offers more than 700 tests using advanced technology and quality standards that comply with global best practices, Vermillion said.